The current status and future directions of hepatitis B antiviral drug discovery

Expert Opinion on Drug Discovery

Volumn 12, Issue 1, 2017, Pages 5-15

  Tang, Liudi ^a   Zhao, Qiong ^b   Wu, Shuo ^b   Cheng, Junjun ^b   Chang, Jinhong ^b   Guo, Ju Tao ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b BARUCH S BLUMBERG INSTITUTE   (United States)

Author keywords

Capsid assembly inhibitor; cccDNA; DNA polymerase inhibitor; gene editing; immunotherapy; RNA interference

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY DNA; HEPATITIS B SURFACE ANTIGEN; VIRAL PROTEIN; VIRUS ANTIGEN; VIRUS MESSENGER RNA; VIRUS RNA; CIRCULAR DNA; VIRUS DNA;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; DNA REPLICATION; GENE INACTIVATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; LIVER CELL CARCINOMA; MORTALITY RISK; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; RNA VIRUS; SEROCONVERSION; SEROLOGY; VACCINATION; VIRAL CLEARANCE; VIRUS ASSEMBLY; VIRUS ENTRY; VIRUS INACTIVATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; ANIMAL; BLOOD; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; PROCEDURES; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DNA, CIRCULAR; DNA, VIRAL; DRUG DESIGN; DRUG DISCOVERY; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY; VIRUS REPLICATION;

EID: 85002761696     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2017.1255195     Document Type: Review

References (98)

1. Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–2219. DOI:10.1016/j.vaccine.2011.12.116
2. Liu F, Campagna M, Qi Y, et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog. 2013;9(9):e1003613. DOI:10.1371/journal.ppat.1003613
3. Xu C, Guo H, Pan XB, et al. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol. 2010;84(18):9332–9340. DOI:10.1128/JVI.00918-10
4. Belloni L, Allweiss L, Guerrieri F, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012;122(2):529–537. DOI:10.1172/JCI58847
5. Thimme R, Dandri M., Dissecting the divergent effects of interferon-alpha on immune cells:time to rethink combination therapy in chronic hepatitis B? J Hepatol. 2013;58(2):205–209. DOI:10.1016/j.jhep.2012.11.007
6. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 2009;49(5 Suppl):S112–21. DOI:10.1002/hep.22920
7. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology. 2009;49(5 Suppl):S103–11. DOI:10.1002/hep.22956
8. Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T- lymphocyte response. Nat Med. 1996;2(10):1104–1108.
9. Block TM, Gish R, Guo H, et al. Chronic hepatitis B:what should be the goal for new therapies? Antiviral Res. 2013;98(1):27–34. DOI:10.1016/j.antiviral.2013.01.006
10. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell. 1986;47:451–460.
11. Wu TT, Coates L, Aldrich CE, et al. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology. 1990;175(1):255–261.
12. Newbold JE, Xin H, Tencza M, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995;69(6):3350–3357.
13. Zhu Y, Yamamoto T, Cullen J, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol. 2001;75(1):311–322. DOI:10.1128/JVI.75.1.311-322.2001
14. Yokosuka O, Omata M, Imazeki F, et al. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment:analysis of intrahepatic replicative hepatitis B virus DNA. Hepatololgy. 1985;5:707–713.
15. Chang J, Guo F, Zhao X, et al. Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharm Sin B. 2014;4(4):248–257. DOI:10.1016/j.apsb.2014.05.002
16. Chang J, Guo JT. Treatment of chronic hepatitis B with pattern recognition receptor agonists:current status and potential for a cure. Antiviral Res. 2015;121:152–159. DOI:10.1016/j.antiviral.2015.07.006
17. Zhang E, Kosinska A, Lu M, et al. Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus:search for the “magic bullet” to kill cccDNA. Antiviral Res. 2015;123:193–203. DOI:10.1016/j.antiviral.2015.10.009
18. Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology. 2007;46(6):1759–1768. DOI:10.1002/hep.21896
19. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049. DOI:10.7554/eLife.00049• This landmark paper identifies sodium taurocholate cotransporting polypeptide (NTCP) as the bona fide receptor of HBV and HDV. This discovery not only helps to improve HBV infection cell culture system, but also identifies a therapeutic target for inhibition of HBV and HDV infection.
20. Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146(4):1070–1083. DOI:10.1053/j.gastro.2013.12.024
21. Macovei A, Radulescu C, Lazar C, et al. Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells. J Virol. 2010;84(1):243–253. DOI:10.1128/JVI.01207-09
22. Verrier ER, Colpitts CC, Bach C, et al. A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. Hepatology. 2016;63(1):35–48. DOI:10.1002/hep.28013
23. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol. 2008;26(3):335–341. DOI:10.1038/nbt1389
24. Volz T, Allweiss L, Ben MM, et al. The entry inhibitor myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58(5):861–867. DOI:10.1016/j.jhep.2012.12.008
25. Blank A, Markert C, Hohmann N, et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol. 2016. DOI:10.1016/j.jhep.2016.04.013
26. Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B:first results of a phase Ib/IIa study. J Hepatol. 2016. DOI:10.1016/j.jhep.2016.04.016
27. Nkongolo S, Ni Y, Lempp FA, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol. 2014;60(4):723–731. DOI:10.1016/j.jhep.2013.11.022• This paper shows that myrcludex B, a first-in-class HBV/HDV entry inhibitor, significantly reduces HDV load and normalizes liver function as well as demonstrates a synergistic effect with pegylated IFN-alpha in 26 weeks of mono- and combinatory therapies of chronic hepatitis D.
28. Watashi K, Sluder A, Daito T, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology. 2014;59(5):1726–1737. DOI:10.1002/hep.26982
29. Urban S, Bartenschlager R, Kubitz R, et al. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147(1):48–64. DOI:10.1053/j.gastro.2014.04.030
30. Yan H, Liu Y, Sui J, et al. NTCP opens the door for hepatitis B virus infection. Antiviral Res. 2015;121:24–30. DOI:10.1016/j.antiviral.2015.06.002
31. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479-480:672–686. DOI:10.1016/j.virol.2015.02.031
32. Liang TJ, Block TM, McMahon BJ, et al. Present and future therapies of hepatitis B:from discovery to cure. Hepatology. 2015;62(6):1893–1908. DOI:10.1002/hep.28025
33. Zhang P, Liu F, Guo F, et al. Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors. Antiviral Res. 2016;131:40–48. DOI:10.1016/j.antiviral.2016.04.007
34. Clark DN, Hu J. Hepatitis B virus reverse transcriptase - target of current antiviral therapy and future drug development. Antiviral Res. 2015;123:132–137. DOI:10.1016/j.antiviral.2015.09.011
35. Tavis JE, Cheng X, Hu Y, et al. The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS Pathog. 2013;9(1):e1003125. DOI:10.1371/journal.ppat.1003125
36. Hu Y, Cheng X, Cao F, et al. Beta-thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Res. 2013;99(3):221–229. DOI:10.1016/j.antiviral.2013.06.007
37. Cai CW, Lomonosova E, Moran EA, et al. Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. Antiviral Res. 2014;108:48–55. DOI:10.1016/j.antiviral.2014.05.007
38. Lu G, Lomonosova E, Cheng X, et al. Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity. Antimicrob Agents Chemother. 2015;59(2):1070–1079. DOI:10.1128/AAC.04617-14
39. Tavis JE, Lomonosova E. The hepatitis B virus ribonuclease H as a drug target. Antiviral Res. 2015;118:132–138. DOI:10.1016/j.antiviral.2015.04.002
40. Hu J, Flores D, Toft D, et al. Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J Virol. 2004;78(23):13122–13131. DOI:10.1128/JVI.78.23.13122-13131.2004
41. Stray SJ, Bourne CR, Punna S, et al. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci USA. 2005;102(23):8138–8143. DOI:10.1073/pnas.0409732102
42. Stray SJ, Zlotnick A. BAY 41-4109 has multiple effects on hepatitis B virus capsid assembly. J Mol Recognit. 2006;19(6):542–548. DOI:10.1002/jmr.801
43. Bourne CR, Finn MG, Zlotnick A. Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1. J Virol. 2006;80(22):11055–11061. DOI:10.1128/JVI.00933-06
44. Wu G, Liu B, Zhang Y, et al. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother. 2013;57(11):5344–5354. DOI:10.1128/AAC.01091-13
45. Campagna MR, Liu F, Mao R, et al. Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol. 2013;87:6931–6942. DOI:10.1128/JVI.00582-13
46. King RW, Ladner SK, Miller TJ, et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L- 2ʹ,3ʹ-dideoxy-3ʹ-thiacytidine [published erratum appears in Antimicrob Agents Chemother 1999 Mar;43(3):726]. Antimicrob Agents Chemother. 1998;42(12):3179–3186.
47. Yang L, Wang YJ, Chen HJ, et al. Effect of a hepatitis B virus inhibitor, NZ-4, on capsid formation. Antiviral Res. 2016;125:25–33. DOI:10.1016/j.antiviral.2015.11.004
48. Wang YJ, Lu D, Xu YB, et al. A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation. Antimicrob Agents Chemother. 2015;59(11):7061–7072. DOI:10.1128/AAC.01558-15
49. Katen SP, Tan Z, Chirapu SR, et al. Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure. Structure. 2013;21(8):1406–1416. DOI:10.1016/j.str.2013.06.013
50. Klumpp K, Lam AM, Lukacs C, et al. High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein. Proc Natl Acad Sci USA. 2015;112(49):15196–15201. DOI:10.1073/pnas.1513803112• This paper reports a high resolution crystal structure of a HAP derivative-bound HBV capsid. The structure reveals that improvement in antiviral potency of HAP derivatives can be achieved by improving in their stabilization of core protein dimer interaction and thus provides clear avenues for compound optimization.
51. Tan Z, Pionek K, Unchwaniwala N, et al. The interface between hepatitis B virus capsid proteins affects self-assembly, pregenomic RNA packaging, and reverse transcription. J Virol. 2015;89(6):3275–3284. DOI:10.1128/JVI.03545-14
52. Qiu Z, Lin X, Zhou M, et al. Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B Virus (HBV) capsid inhibitors. J Med Chem. 2016. DOI:10.1021/acs.jmedchem.6b00879
53. Guo JT, Guo H. Metabolism and function of hepatitis B virus cccDNA:implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral Res. 2015;122:91–100. DOI:10.1016/j.antiviral.2015.08.005
54. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126(7):1750–1758.
55. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005;128(7):1890–1897.
56. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675–684. DOI:10.1002/hep.21282
57. Ramanan V, Shlomai A, Cox DB, et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep. 2015;5:10833. DOI:10.1038/srep10833
58. Liu X, Hao R, Chen S, et al. Inhibition of Hepatitis B Virus by CRISPR/Cas9 System via Targeting the Conserved Regions of Viral Genome. J Gen Virol. 2015;96(8):2252–2261. DOI:10.1099/vir.0.000159
59. Dong C, Qu L, Wang H, et al. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res. 2015;118:110–117. DOI:10.1016/j.antiviral.2015.03.015
60. Ren Q, Li C, Yuan P, et al. A dual-reporter system for real-time monitoring and high-throughput CRISPR/Cas9 library screening of the hepatitis C virus. Sci Rep. 2015;5:8865. DOI:10.1038/srep08865
61. Lin SR, Yang HC, Kuo YT, et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids. 2014;3:e186. DOI:10.1038/mtna.2014.38
62. Seeger C, Sohn JA. Targeting hepatitis B virus with CRISPR/Cas9. Mol Ther Nucleic Acids. 2014;3:e216. DOI:10.1038/mtna.2014.68
63. Seeger C, Sohn JA. Complete spectrum of CRISPR/Cas9-induced mutations on HBV cccDNA. Mol Ther. 2016;24(7):1258–1266. DOI:10.1038/mt.2016.94• This paper reports the complete spectrum of CRISPR/Cas9 editing of cccDNA in HBV-infected hepatoma cells by next generation DNA sequence technology, which provides a basis for further development of the gene-editing technology to inactivate cccDNA in infected hepatocytes in vivo.
64. Wang J, Xu ZW, Liu S, et al. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World J Gastroenterol. 2015;21(32):9554–9565. DOI:10.3748/wjg.v21.i32.9554
65. Pollicino T, Belloni L, Raffa G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology. 2006;130(3):823–837. DOI:10.1053/j.gastro.2006.01.001
66. Tropberger P, Mercier A, Robinson M, et al. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci USA. 2015;112(42):E5715–24. DOI:10.1073/pnas.1518090112
67. Bock CT, Schwinn S, Locarnini S, et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol. 2001;307(1):183–196. DOI:10.1006/jmbi.2000.4481
68. Guo Y-H, Li Y-N, Zhao J-R, et al. HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state. Epigenetics. 2011;6(6):720–726.
69. Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014. DOI:10.1126/science.1243462• This paper reveals an novel mechanism by which host antiviral immune response non-cytopathically eliminates cccDNA from the nuclei of hepatocytes through APOBEC3A or APOBEC3B-mediated cytosine deamination of cccDNA.
70. Lucifora J, Arzberger S, Durantel D, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol. 2011;55(5):996–1003. DOI:10.1016/j.jhep.2011.02.015
71. Tsuge M, Hiraga N, Akiyama R, et al. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice. J Gen Virol. 2010;91(Pt 7):1854–1864. DOI:10.1099/vir.0.019224-0
72. Bouchard MJ, Wang LH, Schneider RJ. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science. 2001;294(5550):2376–2378. DOI:10.1126/science.294.5550.2376
73. Kouwaki T, Okamoto T, Ito A, et al. Hepatocyte factor JMJD5 regulates hepatitis B virus replication through interaction with HBx. J Virol. 2016;90(7):3530–3542. DOI:10.1128/JVI.02776-15
74. Gearhart TL, Bouchard MJ. Replication of the hepatitis B virus requires a calcium-dependent HBx-induced G1 phase arrest of hepatocytes. Virology. 2010;407(1):14–25. DOI:10.1016/j.virol.2010.07.042
75. Melegari M, Wolf SK, Schneider RJ. Hepatitis B virus DNA replication is coordinated by core protein serine phosphorylation and HBx expression. J Virol. 2005;79(15):9810–9820. DOI:10.1128/JVI.79.15.9810-9820.2005
76. Rawat S, Bouchard MJ. The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival. J Virol. 2015;89(2):999–1012. DOI:10.1128/JVI.02440-14
77. Riviere L, Gerossier L, Ducroux A, et al. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J Hepatol. 2015;63(5):1093–1102. DOI:10.1016/j.jhep.2015.06.023
78. van Breugel PC, Robert EI, Mueller H, et al. Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates. Hepatology. 2012;56(6):2116–2124. DOI:10.1002/hep.25928
79. Belloni L, Pollicino T, De Nicola F, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci USA. 2009;106(47):19975–19979. DOI:10.1073/pnas.0908365106
80. Alarcon V, Hernandez S, Rubio L, et al. The enzymes LSD1 and Set1A cooperate with the viral protein HBx to establish an active hepatitis B viral chromatin state. Sci Rep. 2016;6:25901. DOI:10.1038/srep25901
81. Ducroux A, Benhenda S, Riviere L, et al. The Tudor domain protein Spindlin1 is involved in intrinsic antiviral defense against incoming hepatitis B virus and herpes simplex virus type 1. PLoS Pathog. 2014;10(9):e1004343. DOI:10.1371/journal.ppat.1004343
82. Cougot D, Allemand E, Riviere L, et al. Inhibition of PP1 phosphatase activity by HBx:a mechanism for the activation of hepatitis B virus transcription. Sci Signal. 2012;5(205):ra1. DOI:10.1126/scisignal.2003289
83. Decorsiere A, Mueller H, Van Breugel PC, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature. 2016;531(7594):386–389. DOI:10.1038/nature17170• This landmark paper demonstrates that cellular “structural maintenance of chromosomes” (Smc) complex Smc5/6 suppressed the transcription of cccDNA minichromosome and HBx activates the transcription by hijacking DDB1-containing E3 ubiquitin ligase to target the Smc5/6 for degradation.
84. van de Klundert MA, Zaaijer HL, Kootstra NA. Identification of FDA-approved drugs that target hepatitis B virus transcription. J Viral Hepat. 2016;23(3):191–201. DOI:10.1111/jvh.12479
85. Cai D, Wang X, Yan R, et al. Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators. Antiviral Res. 2016;132:26–37. DOI:10.1016/j.antiviral.2016.05.005
86. Bai W, Cui X, Chen R, et al. Re-designed recombinant hepatitis B virus vectors enable efficient delivery of versatile cargo genes to hepatocytes with improved safety. Viruses. 2016;8:5. DOI:10.3390/v8050129
87. Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity. 2014;40(1):13–24. DOI:10.1016/j.immuni.2013.12.010
88. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas:appreciably high rates during a long-term follow-up. Hepatology. 2007;45(5):1187–1192. DOI:10.1002/hep.21612
89. Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology. 2016;150(1):134–44 e10. DOI:10.1053/j.gastro.2015.09.043
90. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther. 2010;15(2):133–143. DOI:10.3851/IMP1497
91. Zhu D, Liu L, Yang D, et al. Clearing persistent extracellular antigen of hepatitis B virus:an Immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination. J Immunol. 2016;196(7):3079–3087. DOI:10.4049/jimmunol.1502061• This paper demonstrates the important role of circulating HBsAg in the induction and maintenance of immune tolerance to HBV in a mice model and requirement of the depletion of circulating HBsAg in the activation of antiviral immune response against HBV by immunization and immunotherapies.
92. Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther. 2013;21(5):973–985. DOI:10.1038/mt.2013.31
93. Xu YB, Yang L, Wang GF, et al. Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion. Antiviral Res. 2014;107:6–15. DOI:10.1016/j.antiviral.2014.04.002
94. Dougherty AM, Guo H, Westby G, et al. A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob Agents Chemother. 2007;51(12):4427–4437. DOI:10.1128/AAC.00541-07
95. Noordeen F, Scougall CA, Grosse A, et al. Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection. PLoS One. 2015;10(11):e0140909. DOI:10.1371/journal.pone.0140909
96. Vaillant A. Nucleic acid polymers:broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection. Antiviral Res. 2016;133:32–40. DOI:10.1016/j.antiviral.2016.07.004
97. Drug watch:compounds in development for chronic hepatitis B. Hepatitis B Foundation; 2016 [cited 2016 Oct17]. Available from:http://www.hepb.org/treatment-and-management/drug-watch/
98. Lanford RE, Guerra B, Chavez D, et al. GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology. 2013;144(7):1508–1517, 17 e1–10. DOI:10.1053/j.gastro.2013.02.003